Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors (AM-003)

  • STATUS
    Recruiting
  • End date
    May 30, 2023
  • participants needed
    32
  • sponsor
    Craig L Slingluff, Jr
Updated on 7 July 2022
cancer
systemic therapy
measurable disease
tumor growth
imiquimod
treatment regimen
residual tumor
metastasis
progressive disease
brain metastases
pd-l1
solid tumors
solid tumour
solid tumor
autoimmune disease
antibody therapy
neurologic symptoms
local ablation therapy

Summary

This study evaluates whether it is safe to Focused Ultrasound Ablation (FUSA) treatments with and without PD-1 blockade and with and without intratumoral poly-ICLC. A device called the Echopulse will be used for the FUSA therapy. Patients will be assigned to 1 of 2 cohorts depending on their disease and treatment status. In Cohort 1, patients will receive FUSA therapy while receiving PD-1 blockade therapy as part of standard clinical care treatment. In Cohort 2, patients who discontinue or are ineligible for PD-1 blockade therapy will undergo FUSA without concurrent systemic therapy, with the goal of utilizing the FUSA to boost the innate immune response. The optional secondary regimen will combine FUSA (+/- PD-1 blockade) with intratumoral poly-ICLC.

Details
Condition Melanoma, Breast Cancer, Merkel Cell Carcinoma, Squamous Cell Cancer, Non Small Cell Lung Cancer, Cervical Cancer, Urothelial Carcinoma, Ovarian Cancer, Hepatocellular Carcinoma, Small-cell Lung Cancer, Microsatellite Instability High, Gastric Cancer, Esophageal Cancer
Treatment Imiquimod, Echopulse, Poly ICLC, Standard of Care PD-1 Therapy
Clinical Study IdentifierNCT04116320
SponsorCraig L Slingluff, Jr
Last Modified on7 July 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Age ≥18 years
Advanced solid tumor with measurable disease
Subject must have failed or have contraindication to standard therapies
For Cohort 1, primary regimen (Regimen 1a): Patients with advanced solid malignancy for which PD1 or PDL1 antibody monotherapy administered on a 3-week schedule is FDA-approved for treatment, who have one or more tumor deposits that are accessible to focused ultrasound treatment, and who are eligible to receive (or to continue to receive) PD1 or PDL1 blockade therapy. Uveal melanoma patients are not eligible for Regimen 1a
Note: Participants eligible for this regimen may receive the primary protocol
therapy (Regimen 1a) concurrent with PD1/PDL1 antibody therapy if
Progressive Disease: subjects with progressive disease following PD1/PDL1 antibody therapy are eligible for this cohort if it is clinically appropriate for them to continue on systemic PD1/PDL1 antibody per the treating clinician even if they did not begin treatment on this trial. Examples may include a patient with a small new lesion but stable disease in other sites, or very slight tumor growth in multiple sites, in a patient without other approved therapy options. Participants who progress following PD1/PDL1 antibody therapy may undergo interval resection of enlarging lesions and still be included in this cohort as long as they have persistent unresectable disease that is accessible to FUSA treatment
Response with persistent disease: subjects who have a clinical response (SD or PR) and have residual lesion(s) accessible to FUSA treatment. Participants with PR are only eligible if it is clinically appropriate for them to continue on PD1/PDL1 therapy per the judgement of the treating clinician
Stable disease: The majority of clinical responses to PD1/PDL1 blockade occur within 12 weeks but may occur much later. Routine clinical practice commonly includes continuation of PD1 antibody therapy for 1-2 years for patients with stable disease on that therapy. Thus, patients with SD after 12 weeks of PD1/PDL1 therapy per RECIST criteria may be eligible for Regimen 1a if their disease has remained stable on therapy and if their treating provider recommends continuation of PD1/PDL1 therapy even if they were not treated on this trial
For Cohort 1, secondary regimen (Regimen 2a): For those patients treated with primary
regimen 1a, select participants may be enrolled in a secondary regimen. This
would include participants in the following scenarios
Stable disease
Initial response followed by progression at treated lesion or separate site, after discontinuation of PD-1/PD-L1 antibody. If there is a response and then progression at the site treated in Regimen 1 and the residual tumor meets inclusion criteria, this lesion may be re-treated on the secondary regimen
Initial partial response but still persistent disease at the treated lesion
Participants with lesions unique from the lesion treated in regimen 1 may enroll in regimen 2 and have additional lesion(s) treated, as long as they meet all inclusion criteria requirements. Up to three lesions may be treated in the second regimen
Patients enrolling to Regimen 2a must have a target lesion amenable to intratumoral
injection with polyICLC per the treating clinician's discretion. The lesion(s) to be
FUSA treated in regimen 2 do not need to include the lesion targeted in regimen 1. The
patient must remain eligible for PD1/PDL1 Ab therapy
For Cohort 2, primary regimen (Regimen 1b): The following patient subsets would be
eligible for the Cohort 2 primary regimen, as long as they have failed (progressed or
not tolerated) or are not eligible for all effective available approved therapies
regimen
known to confer clinical benefit
Patients with advanced solid malignancy for which PD1 or PDL1 blockade is not
FDA-approved
Patients with advanced solid malignancies for which PD1 or PDL1 blockade is FDA
approved but who are not eligible to receive that therapy because of prior
Patients with metastatic uveal melanoma
failure, toxicity, baseline autoimmune disease, or frailty
Patients who previously responded to PD1/PDL1 therapy but then progressed, if
there are no other systemic therapies available to them
Patients who were previously undergoing PD-1 blockade therapy must not have received a
dose within 4 weeks prior to FUSA treatment
For Cohort 2, secondary regimen (Regimen 2b): For those patients treated with primary
regimen 1a or 1b, select participants may be enrolled in a secondary regimen. This
would include participants in the following scenarios
Stable disease
Response in lesion treated in regimen 1, but persistent disease or progression in
Initial partial response but still persistent disease at the treated lesion
a separate lesion
Initial response followed by progression at the treated lesion after
discontinuation of PD-1/PD-L1 antibody. If there is a response and then
progression at the site treated in Regimen 1 and the residual tumor meets
inclusion criteria, this lesion may be re-treated on the secondary regimen. For
participants who progress at a site unique from the treated lesion, they may
enroll in Regimen 2 and have this new lesion treated, as long as they meet all
inclusion criteria requirements
Participants with lesions unique from the lesion treated in regimen 1 may enroll
in regimen 2 and have additional lesion(s) treated, as long as they meet all
inclusion criteria requirements. Up to three lesions may be treated in the second
For FUSA
Patients enrolling to Regimen 2b must have a target lesion amenable to intratumoral
injection with polyICLC per the treating clinician's discretion. The lesion to be FUSA
treated in regimen 2 does not need to be the same lesion targeted in regimen 1
Crossover from primary regimen 1a is allowed if the patient is no longer eligible for
continued PD1/PDL1 Ab therapy (e.g. due to autoimmune toxicity), and if there is no
other effective systemic therapy option. The length between the FUSA treatments in
regimen 1 and regimen 2 should be no less than 6 weeks. Patients who experienced an
unanticipated device effect in the primary regimen are not eligible for the secondary
For Biopsies
regimen
Biopsies may be completed with or without image guidance
One or more dermal, subcutaneous or nodal metastases from an advanced solid tumor. The
metastases need to be accessible for FUSA and for biopsy
The targeted lesion(s) must be visible by ultrasound imaging and meet the following
provided
criteria. Brain lesions may not be targeted for treatment
The tumor site that was previously radiated has progressed
Approximately 1 cm (or more) diameter of treatable tumor volume for lesions to be
treated with FUSA
The target treatment area needs to be contained within a region at least 5 mm
No brain metastasis is > 2 cm in diameter at the time of registration
from the skin surface and less than or equal to 23 mm from the skin surface
Neurologic symptoms have returned to baseline
The target treatment area must be at a safe distance from all critical
There is no evidence of new or enlarging brain metastases
structures, including but not limited to ribs or other bony structures, vital
organs, named blood vessels or nerves
The critical structures, with the exception of the skin, will not be in the
pre-focal ultrasound path
The anterior-posterior dimension of the treatment area by US should be no less
than 9mm
Lesions that have been selected for focused ultrasound or lesions that have been
selected for biopsies as untreated controls may have been previously radiated
A baseline biopsy of the tumor site is obtained following progression and prior
to study entry
ECOG performance status 0-2
Subjects with brain metastases may participate if all of the following are true
There has been no evident growth of any brain metastasis since the most recent
treatment
Subjects are not using steroids for at least 7 days prior to registration
Regardless of dose, however, subjects who are on a steroid taper for management
of brain metastases are not eligible until 7 days after completion of that
steroid taper
Brain metastases will not be targeted for FUSA treatment
Adequate organ function
Ability and willingness to give informed consent

Exclusion Criteria

A subject will be excluded from participating in the trial if the subject
Immune therapies including
checkpoint blockade therapies other than anti-PD-1/PD-L1 antibodies
antibodies to costimulatory molecules (e.g. CD27, CD137)
small molecule immune therapies (e.g. IDO1 inhibitor)
Cytotoxic chemotherapy for cancer
Allergy desensitization injections
High doses of systemic corticosteroids, with the following qualifications and
exceptions
Topical and nasal corticosteroids are acceptable
Targeted therapies specific for mutated BRAF or for MEK
Live vaccine
Has received the following medications or treatments at any time within 3 weeks of
Has an active infection requiring systemic therapy
study day 1
interferon (e.g. Intron-A®)
Note: The following are not exclusionary
Clinical evidence of vitiligo
Other forms of depigmenting illness
Mild arthritis requiring NSAID medications
Has received the following medications or treatments at any time within 4 weeks of
study day 1
Radiation therapy (Note: Stereotactic radiotherapy, such as gamma knife, can be
used ≥ 1 week prior to registration)
Squamous cell cancer of the skin without known metastasis
Basal cell cancer of the skin without known metastasis
Daily doses of 10 mg or less prednisone (or equivalent) per day administered
Carcinoma in situ of the breast (DCIS or LCIS)
parenterally or orally are allowed in patients with normal adrenal and
pituitary function
In patients with adrenal or pituitary insufficiency replacement steroid
doses are allowed
Inhaled steroids (e.g.: Advair®, Flovent®, Azmacort®) are permitted at low
doses (less than 500 mcg fluticasone per day, or equivalent)
Growth factors (e.g. Procrit®, Aranesp®, Neulasta®)
Interleukins (e.g. Proleukin®)
Any investigational therapeutic agent (participation in the UVA AM004 clinical
trial is permitted)
Has a known addiction to alcohol or drugs and is actively taking those agents, or has
recently (within 1 year) taken these agents or has ongoing illicit IV drug use
Is HIV positive or has evidence of active Hepatitis B or C virus with some exceptions
Is currently receiving nitrosoureas or has received this therapy within the preceding
weeks
Is pregnant or breastfeeding. Female participants of childbearing potential must have
a negative pregnancy test obtained within 2 weeks prior to registration. Males and
females must agree, in the consent form, to use effective birth control methods during
the course of treatment and following treatment in accordance with the labeling
guidelines for each approved therapy
Has a medical contraindication or potential problem in complying with the requirements
of the protocol in the opinion of the investigator
Has Class III or IV heart disease as classified according to the New York Heart
Association
Has had prior autoimmune disorders requiring cytotoxic or immunosuppressive therapy,or
autoimmune disorders with visceral involvement. Participants with an active autoimmune
disorder requiring these therapies are also excluded
The presence of laboratory evidence of autoimmune disease (e.g. positive ANA
titer) without symptoms
A history of immune-related adverse events with immune therapy, if the
immune-related adverse events have resolved to grade 1 or lower
History of another cancer
Note: the following diagnoses are exceptions and are permitted as long as they have
been treated successfully and without clinical evidence of disease
Any cancer that has been treated successfully, without evidence of subsequent
recurrence or metastasis for over 5 years
Any cancer without distant metastasis that has been treated successfully, without
evidence of recurrence or metastasis for over 2 years
Carcinoma in situ of the cervix
12) Previous treatment with polyICLC within 4 weeks. If a subject was previously
treated with intratumoral polyICLC and experienced a significant (grade ≥3) toxicity
related to the polyICLC treatment, the tumor that was treated should not be re-treated
as part of this protocol
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note